Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ARDELYX, INC. (ARDX)

Ardelyx Q3 product revenue rises 19% to $125.5 million; 2026 guidance reaffirmed

Positive Impact 3 of 5 earnings Written later

Ardelyx reported third-quarter 2026 results on November 3, 2026, with total product revenue up 19% to $125.5 million and a net loss narrowing to $0.7 million from $1.0 million a year earlier. The company reiterated its full-year 2026 revenue and operating expense guidance and reported $285.3 million in cash, cash equivalents and short-term investments as of September 30, 2026. Research and development expenses rose 39% and SG&A expenses rose 12% year over year, and the company said the ACCEL Phase 3 trial in chronic idiopathic constipation is fully enrolled.

Key points

  • Total product revenue of $125.5 million for the quarter ended September 30, 2026, versus $105.5 million a year earlier; IBSRELA $96.3 million (up 23%) and XPHOZAH $29.2 million (up 7%).
  • Net loss of $0.7 million, or $(0.00) per share, versus a net loss of $1.0 million a year earlier; R&D expenses were $25.2 million and SG&A expenses were $93.9 million.
  • Full-year 2026 guidance reiterated: IBSRELA revenue $350 million to $370 million, XPHOZAH revenue $110 million to $120 million, and operating expenses below $500 million.
  • Cash and short-term investments of $285.3 million at September 30, 2026, up from $264.7 million at December 31, 2025; topline data from the ACCEL trial expected in the second half of 2027.

The filing

CompanyARDELYX, INC. (ARDX)
Form8-K, current report
Filed with the SECNov 3, 2026, 4:03 PM ET
Accession number0001437402-26-000058

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.